Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.

John D HeissAbhik Ray-ChaudhuryDavid E KleinerDebra J EhrlichGretchen ScottNancy A EdwardsDavid S GoldsteinDima A HammoudPiotr HadaczekVictor S Van LaarShantelle A GraffPeter HerscovitchCodrin LunguMark HallettRussell R LonserKareem A ZaghloulKrystof S Bankiewicz

Published in: Movement disorders : official journal of the Movement Disorder Society (2024)

F-FDOPA-PET signal, suggesting the regenerative potential of AAV2-GDNF in PD. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

Keyphrases

gene therapy
stem cells
poor prognosis
healthcare
mesenchymal stem cells
computed tomography
low dose
case report
mental health
pet ct
positron emission tomography
tissue engineering
risk assessment
meta analyses